CORT Insider Filing: 200-share Purchase and 144-share Withholding Reported

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) reporting person Atabak Mokari, the company's Chief Financial Officer, executed purchases and experienced withholding tied to restricted stock vesting in early September 2025. On 09/02/2025 the Reporting Person purchased 200 shares under a Purchase Plan at a price established by that day's closing price ($71.38), and was also granted 200 Purchase Plan shares recorded at $0.00. On 09/03/2025 the issuer withheld 144 shares to satisfy tax-withholding obligations related to the vesting of restricted stock units. The filing states the Reporting Person beneficially owned 14,321 shares following these transactions and discloses 231, 232, and 775 shares underlying unvested restricted stock awards that vest 100% on the one-year anniversary of their grant dates if conditions are met.

Positive

• Insider purchase of 200 shares under the Purchase Plan on 09/02/2025 at the closing-price-based $71.38 indicates direct CFO participation in company equity
• Detailed disclosure of vesting schedules and tax-withholding provides transparency about the nature and timing of the awards

Negative

• 144 shares were withheld on 09/03/2025 to satisfy tax-withholding obligations, reducing net beneficial ownership
• 1,238 shares underlying restricted awards remain unvested and are subject to one-year vesting conditions, limiting immediate ownership rights

Insights

Financial Analyst

TL;DR: CFO purchased 200 shares at $71.38; modest insider buy with remaining unvested awards and tax-withholding reduced shares.

The transactions show the Chief Financial Officer participated in the company Purchase Plan by acquiring 200 shares at a closing-price-based price of $71.38 on 09/02/2025 and receiving an additional 200 Purchase Plan shares recorded at $0.00. Subsequent withholding of 144 shares on 09/03/2025 satisfied tax obligations tied to vested restricted stock units. Beneficial ownership after activity is reported as 14,321 shares. The filing documents 1,238 shares underlying unvested restricted stock awards granted on three dates that vest fully after one year subject to continued ownership and other conditions.

Corporate Governance Expert

TL;DR: Routine insider participation in equity plan with standard vesting and tax-withholding mechanics; disclosure appears complete.

The Form 4 discloses participation in the 2024 Incentive Award Plan and clarifies vesting schedules and tax-withholding treatment. It specifies that Purchase Plan Shares and restricted stock awards are subject to one-year vesting conditions and that the withholding amount was calculated using the 09/02/2025 closing price. The signature includes an attorney-in-fact filing, and the form references a power of attorney on file with the Commission.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mokari Atabak

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		200(1)	A	$71.38(2)	14,265(3)	D
Common Stock	09/02/2025		A		200(4)	A	$0.00	14,465(3)	D
Common Stock	09/03/2025		F(5)		144	D	$71.38(6)	14,321(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issues on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

6. The closing price on September 2, 2025 was used to calculate the withholding obligation.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari.	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Corcept CFO Atabak Mokari report on Form 4 (CORT)?

He purchased 200 shares under a Purchase Plan on 09/02/2025 at a closing-price-based price of $71.38, was granted 200 Purchase Plan shares recorded at $0.00, and had 144 shares withheld on 09/03/2025 to satisfy tax withholding.

How many shares did Atabak Mokari beneficially own after the reported transactions?

14,321 shares of Corcept common stock were reported as beneficially owned following the transactions.

What unvested restricted stock awards are disclosed in the Form 4 for CORT?

The filing discloses 231, 232, and 775 shares underlying unvested restricted stock awards (totaling 1,238 shares) granted on 12/02/2024, 03/03/2025, and 06/02/2025, which vest 100% on the one-year anniversary of each grant date if conditions are met.

Why were 144 shares withheld according to the Form 4?

The issuer withheld 144 shares to satisfy tax-withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units; the withholding calculation used the 09/02/2025 closing price.

Who signed the Form 4 filing for Atabak Mokari (CORT)?

The Form 4 was signed by Joseph Douglas Lyon as attorney-in-fact for Atabak Mokari on 09/04/2025, and the filing notes a power of attorney is on file with the Commission.